

AMENDMENTS TO THE SPECIFICATION

Please amend the paragraph beginning on page 14, line 15 as follow:

The combined targeting approach of the present invention could employ other target molecules and tissue-specific promoters in addition to the ones disclosed herein. For example, representative example of useful target molecules include receptors and other surface motifs known to be upregulated in tumors, e.g. Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), ErbB2 (Her-2), and Carcinoembryonic antigen (CEA). Similarly, receptors and surface accessible molecules present on various normal tissues could be exploited including PECAM E-selectin and ICAM on endothelial cells and the urokinase plasminogen activator receptor on airway epithelium. Furthermore, cytokine and other growth factor receptors known to be upregulated in various pathological states could also be exploited. In addition to known and recognized markers, recently discovered ligands (including peptides, single-chain antibodies and derivative thereof) identified by phage-panning technology or similar procedures could also be included – examples include the “SIGYPLP” (SEQ ID NO. 1) peptide

which has affinity for endothelium and the “SSS-10” peptides which has selectivity for airway epithelium.